A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous.

Slides:

Advertisements

Similar presentations

On behalf of all PROTECT II Investigators

Advertisements

Trial profile Fox K et al. Lancet 2008;372:

Clinic of Cardiovascular and Thorax Surgery Bad Rothenfelde, Germany

M Gaudino. 2 Loop FD et al NEJM 1986 Arterial conduits used for coronary artery bypass grafting - Internal Thoracic Artery - Radial Artery - Right.

Genous™ endothelial progenitor cell capturing stent vs. the Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Elective Intra-aortic Balloon Counterpulsation During.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38.

Increased Risk for Heart Valve Disease Associated With Antiphospholipid Antibodies in Patients With Systemic Lupus ErythematosusClinical Perspective by.

Catheter Ablation of Atrial Fibrillation by Roderick Tung, Eric Buch, and Kalyanam Shivkumar Circulation Volume 126(2): July 10, 2012 Copyright.

Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity by Dariush Mozaffarian Circulation Volume 133(2): January 12, 2016.

Can Adenosine 5′-Triphosphate Be Used to Select Treatment in Severe Vasovagal Syndrome? by Daniel Flammang, Timothy Church, Marc Waynberger, Annick Chassing,

Pulmonary artery catheterization in acute coronary syndromes: Insights from the GUSTO IIb and GUSTO III trials Mauricio G. Cohen, MD, Robert V. Kelly,

Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: A comparison of fractional flow reserve–guided.

Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.

Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India by Rohina Joshi, Clara K. Chow,

Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei.

Factors associated with postoperative atrial fibrillation and other adverse events after cardiac surgery Emmanuel Akintoye, MD, MPH, Frank Sellke, MD,

Comparison of Bare-Metal Stents and Drug-Eluting Stents in Coronary Ostial Lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry)

Circ Cardiovasc Qual Outcomes

Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction by Jordi Matías-Guiu, José M. Ferro, José Alvarez-Sabín,

Circ Cardiovasc Interv

Three-dimensional Mapping of the Initiation of Nonsustained Ventricular Tachycardia in the Human Heart by Mina K. Chung, Steven M. Pogwizd, Dave P. Miller,

by Yehuda G. Wolf, Christopher K. Zarins, Geoffrey D

Spontaneous Coronary Artery Dissection

Atrial Fibrillation and Mortality in Heart FailureClinical Perspective

Circ Cardiovasc Interv

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Site Selection and Performance in Clinical Trials

Modest Increase in Peak VO2 Is Related to Better Clinical Outcomes in Chronic Heart Failure PatientsClinical Perspective by Ann M. Swank, John Horton,

Behavior and Biology: The Basic Sciences for AHA Action

by Thomas Monks, Martin Pitt, Ken Stein, and Martin James

Circ Cardiovasc Interv

Relative Distributions

Circ Cardiovasc Qual Outcomes

Contribution of Stroke to the Cochrane Stroke Group Trials Register

New Frontiers in Cardiology

Circ Arrhythm Electrophysiol

Virtual Reality in Stroke Rehabilitation

Ahead of the Curve by Alun D. Hughes Hypertension Volume 64(5):

by Nick E. J. West, Peter N. Ruygrok, Clemens M. C. Disco, Mark W. I

Randomized Clinical Trial of Therapeutic Exercise in Subacute Stroke

by Alexander Leaf, Christine M

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Risk of Recurrent Cardiac Events After Onset of Menopause in Women With Congenital Long-QT Syndrome Types 1 and 2Clinical Perspective by Jonathan Buber,

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

Pulmonary artery catheterization in acute coronary syndromes: Insights from the GUSTO IIb and GUSTO III trials Mauricio G. Cohen, MD, Robert V. Kelly,

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): Immediate and long-term results Alfredo Rodriguez,

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme.

Off-pump versus on-pump coronary artery bypass grafting: A systematic review and meta-analysis of propensity score analyses Oliver Kuss, PhD, Benita.

Flow of Patients Through the Trial

Effect of metronidazole versus standard care on length of stay of patients admitted with severe infectious mononucleosis: a randomized controlled trial

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

MATRIX: Radial vs. Femoral

Glenn N. Levine et al. JACC 2011;58:e44-e122

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Jenna Barton, MSN, RN-C, PCCN

Presentation transcript:

A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary InterventionClinical Perspective by William W. O'Neill, Neal S. Kleiman, Jeffrey Moses, Jose P.S. Henriques, Simon Dixon, Joseph Massaro, Igor Palacios, Brijeshwar Maini, Suresh Mulukutla, Vladimír Džavík, Jeffrey Popma, Pamela S. Douglas, and Magnus Ohman Circulation Volume 126(14): October 2, 2012 Copyright © American Heart Association, Inc. All rights reserved.

Study flow. William W. O'Neill et al. Circulation. 2012;126: Copyright © American Heart Association, Inc. All rights reserved.

Kaplan–Meier curves of major adverse events to 90 days. William W. O'Neill et al. Circulation. 2012;126: Copyright © American Heart Association, Inc. All rights reserved.

Prespecified prospectively defined subgroup analysis: intent-to-treat population. William W. O'Neill et al. Circulation. 2012;126: Copyright © American Heart Association, Inc. All rights reserved.

Prespecified prospectively defined subgroup analysis: per protocol population. William W. O'Neill et al. Circulation. 2012;126: Copyright © American Heart Association, Inc. All rights reserved.

Ninety-day major adverse events rates over the course of the trial (intent-to-treat population). William W. O'Neill et al. Circulation. 2012;126: Copyright © American Heart Association, Inc. All rights reserved.